"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Descriptor ID |
D000970
|
MeSH Number(s) |
D27.505.954.248
|
Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 |
1995 | 2 | 4 | 6 |
1997 | 1 | 0 | 1 |
1998 | 5 | 1 | 6 |
1999 | 2 | 1 | 3 |
2000 | 3 | 1 | 4 |
2001 | 3 | 2 | 5 |
2002 | 2 | 1 | 3 |
2003 | 6 | 2 | 8 |
2004 | 9 | 2 | 11 |
2005 | 3 | 2 | 5 |
2006 | 4 | 2 | 6 |
2007 | 10 | 1 | 11 |
2008 | 6 | 1 | 7 |
2009 | 6 | 3 | 9 |
2010 | 7 | 2 | 9 |
2011 | 3 | 3 | 6 |
2012 | 7 | 2 | 9 |
2013 | 11 | 1 | 12 |
2014 | 5 | 2 | 7 |
2015 | 3 | 0 | 3 |
2016 | 3 | 6 | 9 |
2017 | 1 | 3 | 4 |
2018 | 4 | 1 | 5 |
2019 | 4 | 1 | 5 |
2020 | 3 | 1 | 4 |
2021 | 1 | 3 | 4 |
2022 | 3 | 0 | 3 |
2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023 07 11; 7(13):2983-2993.
-
Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department? J Emerg Med. 2023 Jan; 64(1):111-118.
-
Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs Today (Barc). 2022 Aug; 58(8):407-423.
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
-
Venetoclax ramp-up with concurrent voriconazole in a patient with chronic lymphocytic leukemia. J Oncol Pharm Pract. 2022 Dec; 28(8):1898-1901.
-
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. Cancer Discov. 2021 10; 11(10):2544-2563.
-
Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma. Laryngoscope. 2021 11; 131(11):E2727-E2735.
-
Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme. World Neurosurg. 2021 05; 149:e1026-e1037.
-
Characterization of Dopamine Receptor Associated Drugs on the Proliferation and Apoptosis of Prostate Cancer Cell Lines. Anticancer Agents Med Chem. 2021; 21(9):1160-1171.
-
Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections. Molecules. 2020 Nov 01; 25(21).